31May

In gastric cancer no treatment till date has shown such a strong data, Definately Enhetru will be positioned much ahead of Kadcyla

Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: A randomized, phase II, multicenter, open-label study (DESTINY-Gastric01)


Abstract No : 4513

Abstract Type : Poster Discussion Session

Indication : HER2+ gastric or gastroesophageal junction (GEJ) adenocarcinoma

Intervention : Enhertu (Trastuzumab deruxtecan)

Company : Daiichi Sankyo

Technology : Antibody-Drug Conjugate (ADC)


Results:

Enhertu shrank tumors in 42.9% of patients with HER2-positive stomach cancer that had progressed after at least two lines of treatment, more than three times that of the 12.5% posted by investigator’s choice of chemotherapy


Conclusion:

T-DXd demonstrated statistically significant and clinically meaningful improvements in ORR and OS compared with standard chemotherapy (paclitaxel or irinotecan) in patients with HER2+ advanced gastric or GEJ adenocarcinoma


Commentary:

In gastric cancer no treatment till date has shown such a strong data, Definately Enhetru will be positioned much ahead of Kadcyla.


Refer to Gastric Cancer Market report for detailed Insights.